Advertisement

A phase 2 study of brentuximab vedotin in patients with CD30-positive advanced systemic mastocytosis

Jason Gotlib, John H. Baird, Tracy I. George, Cheryl Langford, Isabel Reyes, Justin Abuel, Cecelia Perkins, Kurt Schroeder, Prithviraj Bose and Srdan Verstovsek

Article Information

Citation 
vol. 3 no. 15 2264-2271
PubMed 

Print ISSN 
Online ISSN 
History 
  • Submitted March 13, 2019
  • Accepted April 28, 2019
  • Published online July 26, 2019.


Contributors 
  • Jason Gotlib, 1Division of Hematology, Stanford Cancer Institute, Stanford, CA;
  • John H. Baird, 1Division of Hematology, Stanford Cancer Institute, Stanford, CA;
  • Tracy I. George, 2Department of Pathology, University of New Mexico, Albuquerque, NM; and
  • Cheryl Langford, 1Division of Hematology, Stanford Cancer Institute, Stanford, CA;
  • Isabel Reyes, 1Division of Hematology, Stanford Cancer Institute, Stanford, CA;
  • Justin Abuel, 1Division of Hematology, Stanford Cancer Institute, Stanford, CA;
  • Cecelia Perkins, 1Division of Hematology, Stanford Cancer Institute, Stanford, CA;
  • Kurt Schroeder, 3Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
  • Prithviraj Bose, 3Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
  • Srdan Verstovsek, 3Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

Altmetric.com Statistics

The Altmetric score is a weighted count of online attention designed to reflect the volume and reach of online engagement surrounding an individual research output